CNBC's Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid.
They have a plan — Vertex," Cramer said on "Squawk on the Street."
Vertex — which makes most of its revenue from cystic fibrosis treatment Trikafta — has late-stage trials underway for the pain drug, known as VX-548.
"I do believe that if they have something, it would be the largest market opportunity in the world," Cramer said, adding that late-stage study results for VX-548 are expected "within the year."
The firm, which has a buy-equivalent rating on Vertex shares, said it sees similarities between the current pain market and the obesity market one to two years ago.
Persons:
CNBC's Jim Cramer, Cramer, —, Jim Cramer's, Eli Lilly, Mounjaro, Lilly
Organizations:
Vertex Pharmaceuticals, VX, Leerink Partners, Charitable Trust, CNBC, Club, U.S